PAH diagnosis timing study
Part of Heart & circulation, Lungs & breathing clinical trials.
This study looks at the timing between first symptoms and diagnosis of pulmonary arterial hypertension (PAH). It aims to better understand how quickly patients get diagnosed after symptoms appear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with PAH (not other types of pulmonary hypertension).
- Your doctor knows when your first symptoms started (or can estimate it).
- The date of your official PAH diagnosis is known.
- Your PAH diagnosis was confirmed by a right heart catheterization (not just by an echocardiogram or exam).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to validate a questionnaire that measures how well patients understand pulmonary hypertension. If you have been diagnosed with Group 1 Pulmonary Arterial Hypertension (PAH) and can read the questionnaire, you may be able to help researchers make sure it's a useful tool.
This study asks people with pulmonary hypertension and their caregivers about where they get information about the condition. The goal is to understand what sources you use so that doctors can provide better information in the future.
This is a long-term study that enrolls people who have been diagnosed with pulmonary hypertension (high blood pressure in the lung arteries). It collects medical information over time to better understand the condition and what to expect.
This study looks at how sleep-disordered breathing (abnormal breathing during sleep) affects the long-term health of people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. By participating, you will have a sleep study and be followed over time to see how your breathing during sleep relates to your PAH outcomes.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study looks at how environmental factors (like pollutants and lifestyle) may affect pulmonary hypertension. You will fill out questionnaires and provide a small hair sample to help understand these exposures.
Hear when a new Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.